Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Tobacco smoking and risk for idiopathic pulmonary fibrosis: a prospective cohort study in UK Biobank

Vanesa Bellou, Lazaros Belbasis, Athanasios Konstantinidis, Evangelos Evangelou
European Respiratory Journal 2017 50: PA4887; DOI: 10.1183/1393003.congress-2017.PA4887
Vanesa Bellou
1Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lazaros Belbasis
1Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athanasios Konstantinidis
2Department of Respiratory Medicine, University of Ioannina Medical School, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evangelos Evangelou
1Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) is a disease with unknown etiology. Smoking is considered a potential risk factor, but only a limited number of studies is available.

Aims and objectives: Our objective was to examine the association between tobacco smoking and IPF in a large prospective cohort study.

Methods: We used data from UK Biobank, a large population-based study of more than 500,000 individuals. We defined IPF cases as patients with an ICD10 diagnosis of J84.1. We excluded cases with a diagnosis of connective tissue disease (ie rheumatoid arthritis, systematic lupus erythematosus, polyarteritis nodosa, necrotizing vasculopathies, dermatopolymyositis, scleroderma, Sjogren syndrome and sarcoidosis) and cases with an ICD10 diagnosis of J60 – J70 (ie lung diseases due to external agents). We ran logistic regression models for tobacco smoking (ever versus never smokers) and maternal smoking with risk for IPF. The estimates were adjusted for sex and age.

Results: A total of 1,275 cases with an ICD10 code of J84.1 were identified. After exclusion of cases with a connective tissue disease and lung disease due to external agents, 685 cases of IPF and 501,362 controls were identified. The association of ever smoking with risk for IPF presented an odds ratio (OR) of 1.79 (95% confidence interval [CI], 1.50-2.14; P= 4 × 10−10). We also found a novel association between maternal smoking and risk for IPF with an OR of 1.41 (95% CI, 1.19-1.68; P= 1 × 10−4). In a multivariable model combining the two factors, the effect estimates and the level of significance remained unchanged.

Conclusions: Tobacco smoking and maternal smoking are strong and independent risk factors for IPF.

  • Copyright ©the authors 2017
Previous
Back to top
Vol 50 Issue suppl 61 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tobacco smoking and risk for idiopathic pulmonary fibrosis: a prospective cohort study in UK Biobank
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tobacco smoking and risk for idiopathic pulmonary fibrosis: a prospective cohort study in UK Biobank
Vanesa Bellou, Lazaros Belbasis, Athanasios Konstantinidis, Evangelos Evangelou
European Respiratory Journal Sep 2017, 50 (suppl 61) PA4887; DOI: 10.1183/1393003.congress-2017.PA4887

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Tobacco smoking and risk for idiopathic pulmonary fibrosis: a prospective cohort study in UK Biobank
Vanesa Bellou, Lazaros Belbasis, Athanasios Konstantinidis, Evangelos Evangelou
European Respiratory Journal Sep 2017, 50 (suppl 61) PA4887; DOI: 10.1183/1393003.congress-2017.PA4887
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain
  • Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
  • Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
Show more Diffuse Parenchymal Lung Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society